New treatment shows promise

A new, double-barrelled approach to treating C. difficile appears to dramatically reduce recurrence of the debilitating and potentially deadly infection, preliminary testing suggests.

TORONTO — A new, double-barrelled approach to treating C. difficile appears to dramatically reduce recurrence of the debilitating and potentially deadly infection, preliminary testing suggests.

Researchers developed two drugs, called monoclonal antibodies, which are aimed at neutralizing two toxins produced by Clostridium difficile, a common bacterium that can infect the gastrointestinal tract and cause severe diarrhea in vulnerable patients.

A small study found that injections of the monoclonal antibodies along with specific antibiotics used to treat C. difficile reduced the recurrence of the disease by 72 per cent.

“We’re really hopeful that this is a new therapy and a new option for patients,” said Dr. Donna Ambrosino of the University of Massachusetts Medical School, which co-developed the drugs.

“Larger studies will have to be done before it can be licensed and available to patients,” Ambrosino said from Boston. “But we’re quite confident, given these results, that with larger studies that will be shown, and ultimately that this would be a therapy that would prevent those recurrences.”

The study compared 200 patients with C. difficile in 30 centres across the United States and Canada, from July 2006 through April of 2008.

Half were randomly assigned to receive antibiotics plus a single injection of the monoclonal antibodies, while the other half were treated with antibiotics and a shot containing a placebo. Patients were then monitored for almost three months.

The research, published in this week’s New England Journal of Medicine, is what’s called a Phase 2 study, conducted to determine safety of the drugs and optimal dosing. But in analyzing their data, the researchers found a significant difference in how the two groups fared.

Results showed only seven per cent of patients who received the antibodies suffered a recurrence, compared to 25 per cent of those in the placebo group — a 72 per cent difference in the relapse rate.

Of 44 patients infected with the epidemic strain of C. difficile, NAP-1, only eight per cent of those given the antibodies suffered a relapse, versus 32 per cent of those given a dummy shot.

The monoclonal antibodies were developed by the University of Massachusetts’ non-profit MassBiologics arm and Medarex, a subsidiary of Bristol-Myers Squibb. Rights have been licensed to Merck, which would be responsible for undertaking larger studies to confirm the drugs’ effectiveness before seeking government approval to market them.

“I think the statistics are impressive,” said Dr. Dale Gerding, an infectious disease specialist at Loyola University, where lab work on the C. difficile organisms was performed for the study.

“This is a quite effective strategy, it appears,” Gerding said from Chicago. “Getting recurrence rates down to single digits (seven per cent) when your placebo group is running at 25 per cent is really quite significant.”

C. difficile is widespread in the environment, with up to five per cent of the population carrying it without ill effect. But for some patients, taking certain antibiotics or other drugs can disrupt natural flora in the intestinal tract, allowing the bacterium to proliferate.

That can lead to severe diarrhea, bowel disease or potentially fatal blood poisoning.

A virulent epidemic strain, known as NAP-1, killed an estimated 2,000 patients in Quebec in the last 10 years, and other outbreaks of the bug caused scores of deaths in some Ontario hospitals.

C. difficile produces spores that can contaminate surfaces and are difficult to eradicate, making it one of the most common causes of infectious diarrhea in hospitals and long-term care homes.

“What happens, we think, in almost every case is you take the antibiotic, your flora is disrupted and then you also have to ingest or pick up the organism,” said Gerding.

“Then if you lack antibody (against C. difficile), as many elderly people do, then you become symptomatic.”

“We know that if you stay in the hospital after you’ve been treated that your rate of recurrence is higher … presumably that’s because you’re exposed to the organisms more because of the contaminated environments in hospitals.”

“The really distressing part of it is what you went there for, you got taken care of. But now you’ve got this new thing that doesn’t want to go away. And it does extremely debilitate people, especially if they’re older. And it just upsets their recuperation from the other problems and it puts them on medication for months and months and months.”

Gerding said the monoclonal antibody is intended to boost the immune system’s ability to fight off the infection, allowing patients to recover faster.

“The trial results are impressive,” Dr. Lorraine Kyne, a geriatric medicine specialist at University College Dublin, wrote in an accompanying editorial. “This novel non-antibiotic approach to secondary prevention is likely to offer hope to physicians and patients battling C. difficile infection.”

Ambrosino, executive director of MassBiologics and a professor of pediatrics at the University of Massachusetts, said a number of monoclonal antibodies have been developed over the last decade as treatments for certain cancers, rheumatoid arthritis and multiple sclerosis.

Those aimed at C. difficile represent only the second time the drug type has been used successfully against an infectious disease (the other is respiratory syncytial virus in infants), she said, adding that her team is studying other monoclonal antibodies for rabies and hepatitis C.

“I think there’s room for many more infectious diseases to be attacked by monoclonal antibodies, and we’re quite hopeful.”

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

This unicorn was stolen from the small community of Delia, northeast of Drumheller on Friday and was recovered, with its bronze horn broken off, on Saturday. RCMP are looking for information on the suspects.
(Photo from RCMP)
Unicorn statue stolen from Delia recovered

Statue found with horn broken off in field about 15 km from Delia

(Advocate file photo)
Lacombe man whose manslaughter sentence was rejected by judge has new lawyer

Judge rejected proposed seven-year sentence for manslaughter in connection with 2019 homicide

Prime Minister Justin Trudeau holds a news conference at Rideau cottage in Ottawa, on Friday, March 13, 2020. THE CANADIAN PRESS/Fred Chartrand
Liberals to release federal budget with eye on managing crisis, post-pandemic growth

OTTAWA — The federal government will this afternoon unveil its spending plans… Continue reading

Patches are seen on the arm and shoulder of a corrections officer in the segregation unit at the Fraser Valley Institution for Women during a media tour, in Abbotsford, B.C., on Thursday, Oct. 26, 2017. Correctional Service Canada says three inmates at Fraser Valley Institution recently tested positive for COVID-19. THE CANADIAN PRESS/Darryl Dyck
Drumheller Institution inmate dies in custody

Inmate’s April 15 death under investigation

In this image from NASA, NASA's experimental Mars helicopter Ingenuity lands on the surface of Mars Monday, April 19, 2021. The little 4-pound helicopter rose from the dusty red surface into the thin Martian air Monday, achieving the first powered, controlled flight on another planet. (NASA via AP)
NASA’s Mars helicopter takes flight, 1st for another planet

CAPE CANAVERAL, Fla. — NASA’s experimental helicopter Ingenuity rose into the thin… Continue reading

A vial of the Medicago vaccine sits on a surface. CARe Clinic, located in Red Deer, has been selected to participate in the third phase of vaccine study. (Photo courtesy www.medicago.com)
Red Deer clinical research centre participating in plant-based COVID-19 vaccine trial

A Red Deer research centre has been selected to participate in the… Continue reading

In this Feb. 24, 2020, photo, the Olympics rings are reflected on the window of a hotel restaurant as a server with a mask sets up a table, in the Odaiba section of Tokyo. The vaccine rollout in Japan has been very slow with less than 1% vaccinated. This of course is spilling over to concerns about the postponed Tokyo Olympics that open in just over three months.(AP Photo/Jae C. Hong, File)
Will Japanese Olympians be vaccinated ahead of the public?

TOKYO — The vaccine rollout in Japan has been very slow with… Continue reading

PSG's Kylian Mbappe, right, greets Bayern's Lucas Hernandez at the end of the Champions League, second leg, quarterfinal soccer match between Paris Saint Germain and Bayern Munich at the Parc des Princes stadium, in Paris, France, Tuesday, April 13, 2021. (AP Photo/Francois Mori)
PSG, Bayern the big names missing from Super League plan

DÜSSELDORF, Germany — The plan for the new Super League soccer competition… Continue reading

In this image released by Paramount Pictures, Marion Cotillard, left, and Brad Pitt appear in a scene from "Allied." (Daniel Smith/Paramount Pictures via AP)
Leo Carax’s ‘Annette’ to open Cannes Film Festival

Leo Carax’s “Annette,” starring Marion Cotillard and Adam Driver, will open the… Continue reading

From left, Producer Doug Mitchell, actor Chris Hemsworth and director George Miller attend at a press conference to announce the new "Mad Max" film at Fox Studios Australia in Sydney, Monday, April 19, 2021. (Mick Tsikas/AAP Image via AP)
‘Mad Max’ prequel shot in Outback to be released in 2023

SYDNEY, Australia — A prequel to the “Mad Max” movie franchise starring… Continue reading

In this Feb. 1, 2021 file photo, emissions from a coal-fired power plant are silhouetted against the setting sun in Independence, Mo. President Joe Biden faces a vexing task as he convenes a virtual climate summit on Thursday. He is expected to present a nonbinding but symbolic goal to reduce greenhouse gas emissions that will have a tangible impact not only on climate change efforts in the U.S. but throughout the world. (AP Photo/Charlie Riedel, File)
Biden pressed on emissions goal as climate summit nears

WASHINGTON — When President Joe Biden convenes a virtual climate summit on… Continue reading

Women wearing masks wait near an advertisement ahead of the Auto Shanghai 2021 show in Shanghai on Sunday, April 18, 2021. Automakers from around the world are showcasing their latest products this week in the world's biggest market for auto vehicles. (AP Photo/Ng Han Guan)
VW, Ford unveil SUVs at China auto show under virus controls

SHANGHAI — Volkswagen, Ford and Chinese brands unveiled new SUVs for China… Continue reading

Investigators from the Vancouver Police Department were in Chilliwack Saturday, collecting evidence connected to a double homicide. (file photo)
Police investigate shooting death of man outside downtown Vancouver restaurant

Vancouver police say one man was killed in what they believe was… Continue reading

Dr. E. Kwok administers a COVID-19 vaccine to a recipient at a vaccination clinic run by Vancouver Coastal Health, in Richmond, B.C., Saturday, April 10, 2021. THE CANADIAN PRESS/Jonathan Hayward
B.C. to start registering people 18 years and older for COVID-19 vaccines

VICTORIA — The British Columbia government says it’s inviting people 18 years… Continue reading

Most Read